Affiliations: [a] URRMA R&D, Aubagne Cedex, France | [b] Baculovirus et Thérapie, Station de Recherche, CNRS UPS 3044, CNRS GDR 2590, CNRS GDR 2352, 30 380 Saint Christol Lèz Alès, France | [c] CNRS UMR 5236, CNRS GDR 2352. Centre d'Etudes d'Agento Pathogénes, et de Biotechnologie pour la Santé, Montpellier Cedex 5, France
Correspondence:
[*]
Corresponding author: Camille Haslin, URRMA R&D, Centre de Vie Agora Bat C, Zone Industrielle des Paluds, B.P. 1055, 13781 Aubagne Cedex, France. Tel.: +33 4 42 82 42 10; Fax: +33 4 42 70 38 66; E-mail: [email protected].
Abstract: The construction of a recombinant antibody directed against the cellular epitope R7V acquired by HIV during the viral budding has been realized. The c-DNAs encoding the variable regions of the anti-R7V antibody have been cloned from B lymphocytes of a non-progressor patient. Two transfer vectors containing complete coding sequences for heavy and light chains of this antibody were constructed and a recombinant baculovirus was generated by a double recombination between baculovirus DNA and the two transfer vectors. Insect cells infected with this baculovirus produced a complete human anti-R7V immunoglobulin. This recombinant antibody, specific to the R7V peptide, recognizes and neutralizes all clades of HIV1 including resistant viruses, opening new perspectives in anti-HIV therapy.
